Figure 3

Forest plot of the meta-analysis for estimating the RR and 95% CIs for the ORR in the intervention group, compared with that in the control group (RR: 1.64; 95% CI, 1.42–1.90, P = 0.000). Squares indicate study-specific RRs. Horizontal lines crossing the square indicate the 95% CIs. The dashed vertical lines indicate the specific pooled RR. Diamonds indicate the estimated overall effect according to meta-analysis random effect of pooled RRs from all included studies with their corresponding 95% CIs. Favours intervention represents better complete response or partial response in the treatment of anti-PD-1/PD-L1 inhibitors (Atezolizumab, Pembrolizumab, Nivolumab, Avelumab or Durvalumab); Favours control represents better complete response or partial response in the treatment of the control therapies (placebo, chemotherapy, targeted therapy alone or their combination). Herbst 2016-2 mg/kg, 2 mg/kg subset in Herbst 2016; Herbst 2016-10 mg/kg, 10 mg/kg subset in Herbst 2016; Eng-C 2019, combined therapy subset in Eng 2019; Eng-M 2019, monotherapy subset in Eng 2019; Hamid 2017-2 mg/kg, 2 mg/kg subset in Hamid 2017; Hamid 2017-10 mg/kg, 10 mg/kg subset in Hamid 2017.